Brain scan and spinal tap study aims to speed up ataxia drug trials
NCT ID NCT04288128
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at 40 people with spinocerebellar ataxia types 2 and 7, a rare brain disease that affects movement. Researchers used MRI scans and lumbar punctures over one year to track changes in the brain and body. The goal was to find reliable markers that could be used in future trials of experimental gene-targeting drugs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could identify reliable markers to speed up testing of new treatments for spinocerebellar ataxia.
- What could go wrong
- This is an observational study, not a treatment trial. It may not find clear markers, and any findings will need confirmation in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPINOCEREBELLAR ATAXIA TYPE 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut du Cerveau - Paris Brain Institute
Paris, 75013, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict how genetic ataxias progress?
- Could a drug slow rare brain disease? new study uses Real-World data to find out
- Could stem cells help people with spinocerebellar ataxia? new trial aims to find out
- New study sheds light on vision loss in rare genetic brain disorders
- New drug could slow rare brain disease that steals balance
- New study tracks rare disease SCA7 to uncover clues for future treatments